Skip to content
PubMed This is a summary of 54 peer-reviewed journal articles Updated

Research & Literature

Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.

Explore the Literature Visualize citation networks across 54 referenced papers

Top Authors

Anna Šedivá
Charles University
Caterina Cancrini
University of Rome Tor Vergata
Carsten Speckmann
University of Freiburg
Olaf Neth
Instituto de Biomedicina de Sevilla
Stephan R. Ehl
University of Freiburg
Capucine Pïcard
Hôpital Necker-Enfants Malades
Vassilios Lougaris
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Francesca Conti
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Peter Olbrich
Instituto de Biomedicina de Sevilla

Top Institutions

Ranked by publications Top 10 institutions
06

Great North Children's Hospital

Newcastle upon Tyne, United Kingdom

19 papers
08

Instituto de Biomedicina de Sevilla

Seville, Spain

12 papers
10

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Brescia, Italy

24 papers

References

References (54)
  1. 1

    Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.

    Olbrich P, Lorenz M, Cura Daball P, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2016; (27(6)):640-4 doi:10.1111/pai.12585.

    PMID: 27116393
  2. 2

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.

    Elkaim E, Neven B, Bruneau J, et al.

    The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.

    PMID: 27221134
  3. 3

    Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

    Coulter TI, Chandra A, Bacon CM, et al.

    The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.

    PMID: 27555459
  4. 4

    Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

    Wentink M, Dalm V, Lankester AC, et al.

    Clinical immunology (Orlando, Fla.) 2017; (176()):77-86 doi:10.1016/j.clim.2017.01.004.

    PMID: 28104464
  5. 5

    Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.

    Dornan GL, Siempelkamp BD, Jenkins ML, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.

    PMID: 28167755
  6. 6

    Variant PIK3R1 Hypermorphic Mutation and Clinical Phenotypes in a Family with Short Statures, Mild Immunodeficiency and Lymphoma.

    Hauck F, Magg T, Krolo A, et al.

    Klinische Padiatrie 2017; (229(3)):113-117 doi:10.1055/s-0043-104218.

    PMID: 28561224
  7. 7

    Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

    Condliffe AM, Chandra A

    Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.

    PMID: 29556229
  8. 8

    Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

    Maccari ME, Abolhassani H, Aghamohammadi A, et al.

    Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.

    PMID: 29599784
  9. 9

    Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.

    Asano T, Okada S, Tsumura M, et al.

    Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.

    PMID: 29675019
  10. 10

    CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.

    Cura Daball P, Ventura Ferreira MS, Ammann S, et al.

    Immunology and cell biology 2018; (96(10)):1060-1071 doi:10.1111/imcb.12169.

    PMID: 29790605
  11. 11

    Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.

    Pham MN, Cunningham-Rundles C

    Frontiers in pediatrics 2018; (6()):402 doi:10.3389/fped.2018.00402.

    PMID: 30619796
  12. 12

    Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2.

    Hong Y, Nanthapisal S, Omoyinmi E, et al.

    Frontiers in immunology 2019; (10()):2589 doi:10.3389/fimmu.2019.02589.

    PMID: 31781101
  13. 13

    Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.

    Ewertowska M, Grześk E, Urbańczyk A, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020; (16()):22 doi:10.1186/s13223-020-00420-6.

    PMID: 32265996
  14. 14

    [Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].

    Yang QY, Jia YJ, Wang YP, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(5)):413-417 doi:10.3760/cma.j.cn112140-20190925-00614.

    PMID: 32392959
  15. 15

    Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea.

    Kang JM, Kim SK, Kim D, et al.

    Yonsei medical journal 2020; (61(6)):542-546 doi:10.3349/ymj.2020.61.6.542.

    PMID: 32469178
  16. 16

    Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.

    Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E

    Cytometry. Part B, Clinical cytometry 2021; (100(4)):460-466 doi:10.1002/cyto.b.21956.

    PMID: 32961022
  17. 17

    International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome.

    Dimitrova D, Nademi Z, Maccari ME, et al.

    The Journal of allergy and clinical immunology 2022; (149(1)):410-421.e7 doi:10.1016/j.jaci.2021.04.036.

    PMID: 34033842
  18. 18

    Infections in activated PI3K delta syndrome (APDS).

    Brodsky NN, Lucas CL

    Current opinion in immunology 2021; (72()):146-157 doi:10.1016/j.coi.2021.04.010.

    PMID: 34052541
  19. 19

    Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.

    Moreno-Corona N, Chentout L, Poggi L, et al.

    Frontiers in pediatrics 2021; (9()):688022 doi:10.3389/fped.2021.688022.

    PMID: 34249818
  20. 20

    Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.

    Conti F, Catelli A, Cifaldi C, et al.

    Frontiers in pediatrics 2021; (9()):702546 doi:10.3389/fped.2021.702546.

    PMID: 34307262
  21. 21

    Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.

    Rivalta B, Amodio D, Milito C, et al.

    Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.

    PMID: 34540765
  22. 22

    Psychological State of Parents of Children with Primary Immunodeficiencies During the COVID-19 Pandemic.

    Akdağ B, Önder A, Gizli Çoban Ö, et al.

    Pediatric allergy, immunology, and pulmonology 2022; (35(1)):12-18 doi:10.1089/ped.2021.0081.

    PMID: 35180363
  23. 23

    Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.

    Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.

    Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.

    PMID: 35789397
  24. 24

    A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

    Rao VK, Webster S, Šedivá A, et al.

    Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.

    PMID: 36399712
  25. 25

    Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.

    Nguyen T, Lau A, Bier J, et al.

    The Journal of experimental medicine 2023; (220(6)) doi:10.1084/jem.20221020.

    PMID: 36943234
  26. 26

    Leniolisib: First Approval.

    Duggan S, Al-Salama ZT

    Drugs 2023; (83(10)):943-948 doi:10.1007/s40265-023-01895-4.

    PMID: 37256490
  27. 27

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899
  28. 28

    Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.

    Vanselow S, Wahn V, Schuetz C

    Frontiers in immunology 2023; (14()):1208567 doi:10.3389/fimmu.2023.1208567.

    PMID: 37600808
  29. 29

    Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant.

    Tomlinson PR, Knox R, Perisic O, et al.

    bioRxiv : the preprint server for biology 2024; doi:10.1101/2023.11.02.565250.

    PMID: 38077044
  30. 30

    Systematic review of mortality and survival rates for APDS.

    Hanson J, Bonnen PE

    Clinical and experimental medicine 2024; (24(1)):17 doi:10.1007/s10238-023-01259-y.

    PMID: 38280023
  31. 31

    Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.

    Zhao P, Huang J, Fu H, et al.

    Pediatric rheumatology online journal 2024; (22(1)):24 doi:10.1186/s12969-024-00955-7.

    PMID: 38287413
  32. 32

    The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.

    Catelli A, Nanni C, Mulè R, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.

    PMID: 38673479
  33. 33

    [Activated phosphoinositide 3-kinase delta syndrome: report of seven cases].

    Liu QH, Peng L, Huang H, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2024; (26(5)):499-505 doi:10.7499/j.issn.1008-8830.2312065.

    PMID: 38802911
  34. 34

    Health-related quality of life in patients with inborn errors of immunity: A systematic review and meta-analysis.

    Xiao N, Huang X, Yang D, et al.

    Preventive medicine 2024; (186()):108079 doi:10.1016/j.ypmed.2024.108079.

    PMID: 39053518
  35. 35

    Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study.

    Phillips C, Parkinson A, Namsrai T, et al.

    Orphanet journal of rare diseases 2024; (19(1)):297 doi:10.1186/s13023-024-03319-2.

    PMID: 39143641
  36. 36

    Case report on activated PI3K-delta syndrome.

    Crisanto-López IE, Pérez-Arzola AA, Hernández-Castañeda Y, et al.

    Boletin medico del Hospital Infantil de Mexico 2024; (81(4)):245-249 doi:10.24875/BMHIM.23000124.

    PMID: 39236673
  37. 37

    Immunodeficiency: Burden of Illness.

    Hsueh JC, Van Hersh AT, Zhao W

    Allergy and asthma proceedings 2024; (45(5)):294-298 doi:10.2500/aap.2024.45.240060.

    PMID: 39294910
  38. 38

    A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.

    Bildik HN, Esenboga S, Halaclı SO, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.

    PMID: 39312287
  39. 39

    Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.

    Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.

    Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.

    PMID: 39620215
  40. 40

    Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.

    Büsch K, Memmott HL, McLaughlin HM, et al.

    Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.

    PMID: 39636570
  41. 41

    Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome.

    Remiker AS, Lopes JPM, Jesudas R, et al.

    Frontiers in pediatrics 2024; (12()):1494945 doi:10.3389/fped.2024.1494945.

    PMID: 39664282
  42. 42

    Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

    IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ

    Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.

    PMID: 39679264
  43. 43

    Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.

    Barzaghi F, Moratti M, Panza G, et al.

    Journal of clinical immunology 2024; (45(1)):58.

    PMID: 39714594
  44. 44

    Listeria Meningitis as an Indication of Undiagnosed Primary Immune Deficiency, Activated Phosphoinositide 3-Kinase Delta Syndrome: A Case Report.

    Canizci Erdemli P, Öcal Demir S, Bozkurt S, et al.

    The Pediatric infectious disease journal 2025; (44(7)):672-675 doi:10.1097/INF.0000000000004737.

    PMID: 39889727
  45. 45

    Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).

    Neth O, Alsina L, Rivière JG, et al.

    Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.

    PMID: 40028901
  46. 46

    Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS).

    Mahendran M, Upton JEM, Ramasubramanian R, et al.

    Orphanet journal of rare diseases 2025; (20(1)):212 doi:10.1186/s13023-025-03734-z.

    PMID: 40319290
  47. 47

    "It's a Godsend": Parental experiences of genomic testing for paediatric inborn errors of immunity.

    Clark A, DeBortoli E, Blancoe M, et al.

    European journal of human genetics : EJHG 2025; (33(10)):1342-1349 doi:10.1038/s41431-025-01917-7.

    PMID: 40730688
  48. 48

    Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.

    Upton JEM, Williams KW, Cant A, et al.

    PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.

    PMID: 41091701
  49. 49

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  50. 50

    Case Report: Recurrent pulmonary infections with neck masses: a diagnostic challenge and literature review.

    Zhao L, Zhao J, Lu Y

    Frontiers in medicine 2026; (13()):1807946 doi:10.3389/fmed.2026.1807946.

    PMID: 42040580
  51. 51

    Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.

    Zhao X, Ming X, Shang Z, et al.

    Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.

    PMID: 42591980
  52. 52

    Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.

    Rao VK, Šedivá A, Dalm VASH, et al.

    Journal of human immunity 2027; (3(1)) doi:10.70962/jhi.20260040.

    PMID: 42873197
  53. 53

    Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review.

    Hartog NL, Pisarczyk K, Samad M, et al.

    Advances in therapy 2026; doi:10.1007/s12325-026-03833-8.

    PMID: 42932134
  54. 54

    When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity.

    Aydemir S, Durcan G, Nurhan E, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2026; (37(11)).

    PMID: 42969273